

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 April 2024 (04.04.2024)



(10) International Publication Number
WO 2024/073371 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/551 (2006.01)
A61K 31/444 (2006.01) A61K 31/553 (2006.01)
A61K 31/4545 (2006.01) A61P 35/00 (2006.01)
A61K 31/496 (2006.01) C07D 401/14 (2006.01)
A61K 31/497 (2006.01) C07D 473/00 (2006.01)
A61K 31/506 (2006.01) C07D 487/04 (2006.01)
A61K 31/53 (2006.01) C07D 519/00 (2006.01)
A61K 31/55 (2006.01)

(21) International Application Number:

PCT/US2023/075058

(22) International Filing Date:

25 September 2023 (25.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/377,183 26 September 2022 (26.09.2022) US
63/498,770 27 April 2023 (27.04.2023) US
63/508,418 15 June 2023 (15.06.2023) US
63/580,327 01 September 2023 (01.09.2023) US
63/582,697 14 September 2023 (14.09.2023) US

(71) Applicant: **ALTEROME THERAPEUTICS, INC.**
[US/US]; 13520 Evening Creek Drive North, Suite 430, San
Diego, California 92128 (US).

(72) Inventors: **BARTBERGER, Michael David**; 13520
Evening Creek Drive North, Suite 430, San Diego, Cali-
fornia 92128 (US). **DNEPROVSKAIA, Elena V.**; 13520
Evening Creek Drive North, Suite 430, San Diego, Cali-
fornia 92128 (US). **FAN, Yi**; 13520 Evening Creek Drive
North, Suite 430, San Diego, California 92128 (US). **MUR-
PHY, Eric Anthony**; 13520 Evening Creek Drive North,
Suite 430, San Diego, California 92128 (US). **ZHU, Xue-
feng**; 13520 Evening Creek Drive North, Suite 430, San
Diego, California 92128 (US).

(74) Agent: **CLARK, David L.**; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: AKT1 MODULATORS

(57) Abstract: Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and meth-
ods for using the AKT1 inhibitory compounds for the treatment of disease.

WO 2024/073371 A1